Collegium Pharmaceutical (COLL) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $23.19, +0.04% vs the prior close of $23.18.
- Volume 558.64K shares, 0.6x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
COLL ends flat (+0.0%) to $23.19, a 1-month high, 3 up days in a row. Closed at $23.19, +0.04% vs the prior close of $23.18. Day range $22.85–$23.41, opened at $23.40.
COLL daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — COLL ends flat (+0.0%) to $23.19, a 1-month high, 3 up days in a row
- Closed at $23.19, +0.04% vs the prior close of $23.18. Day range $22.85–$23.41, opened at $23.40.
- Volume was 558.64K shares, 0.6x its 50-day average of 902.53K.
- Price is -4.1% vs its 50-day average ($24.19) and -32.6% vs its 200-day average ($34.41).
- 52-week range $21.43–$50.79; today's close sits at 6% of that range, 54.3% below the 52-week high.
- That makes 3 straight gains.
Oct 15, 2026 — COLL rises 3.0% to $23.18, a 1-month high
- Closed at $23.18, +2.98% vs the prior close of $22.51. Day range $23.06–$24.04, opened at $23.06.
- Volume was 1.00M shares, 1.1x its 50-day average of 890.54K.
- Price is -4.7% vs its 50-day average ($24.31) and -32.9% vs its 200-day average ($34.53).
- 52-week range $21.43–$50.79; today's close sits at 6% of that range, 54.4% below the 52-week high.
Oct 14, 2026 — COLL jumps 4.6% to $22.51
- Closed at $22.51, +4.55% vs the prior close of $21.53. Day range $21.47–$22.56, opened at $21.65.
- Volume was 920.20K shares, 1.0x its 50-day average of 880.91K.
- Price is -8.4% vs its 50-day average ($24.56) and -35.1% vs its 200-day average ($34.66).
- 52-week range $21.43–$50.79; today's close sits at 4% of that range, 55.7% below the 52-week high.
Oct 13, 2026 — COLL dips 2.4% to $21.53, a 52-week low, 3 down days in a row
- Closed at $21.53, -2.36% vs the prior close of $22.05. Day range $21.46–$22.21, opened at $22.05.
- Volume was 846.40K shares, 1.0x its 50-day average of 871.47K.
- Price is -13.3% vs its 50-day average ($24.83) and -38.1% vs its 200-day average ($34.80).
- 52-week range $21.43–$50.79; today's close sits at 0% of that range, 57.6% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — COLL ends flat (-0.2%) to $22.05
- Closed at $22.05, -0.18% vs the prior close of $22.09. Day range $21.78–$22.28, opened at $22.14.
- Volume was 528.70K shares, 0.6x its 50-day average of 866.66K.
- Price is -12.2% vs its 50-day average ($25.11) and -36.9% vs its 200-day average ($34.94).
- 52-week range $21.43–$50.79; today's close sits at 2% of that range, 56.6% below the 52-week high.
Oct 9, 2026 — COLL ends flat (-0.1%) to $22.09
- Closed at $22.09, -0.09% vs the prior close of $22.11. Day range $21.77–$22.40, opened at $22.01.
- Volume was 438.30K shares, 0.5x its 50-day average of 862.92K — lighter than usual.
- Price is -12.9% vs its 50-day average ($25.38) and -37.0% vs its 200-day average ($35.07).
- 52-week range $21.43–$50.79; today's close sits at 2% of that range, 56.5% below the 52-week high.
Oct 8, 2026 — COLL rises 0.8% to $22.11, 3 up days in a row
- Closed at $22.11, +0.82% vs the prior close of $21.93. Day range $21.78–$22.18, opened at $22.03.
- Volume was 532.90K shares, 0.6x its 50-day average of 859.26K.
- Price is -13.8% vs its 50-day average ($25.65) and -37.2% vs its 200-day average ($35.21).
- 52-week range $21.43–$50.79; today's close sits at 2% of that range, 56.5% below the 52-week high.
- That makes 3 straight gains.
Oct 7, 2026 — COLL ends flat (+0.2%) to $21.93
- Closed at $21.93, +0.23% vs the prior close of $21.88. Day range $21.73–$22.15, opened at $21.88.
- Volume was 783.50K shares, 0.9x its 50-day average of 848.10K.
- Price is -15.4% vs its 50-day average ($25.94) and -37.9% vs its 200-day average ($35.34).
- 52-week range $21.43–$50.79; today's close sits at 2% of that range, 56.8% below the 52-week high.
Oct 6, 2026 — COLL ends flat (+0.0%) to $21.88
- Closed at $21.88, +0.05% vs the prior close of $21.87. Day range $21.67–$22.32, opened at $22.06.
- Volume was 634.00K shares, 0.8x its 50-day average of 841.61K.
- Price is -16.5% vs its 50-day average ($26.22) and -38.3% vs its 200-day average ($35.48).
- 52-week range $21.43–$50.79; today's close sits at 2% of that range, 56.9% below the 52-week high.
Oct 5, 2026 — COLL dips 0.7% to $21.87
- Closed at $21.87, -0.68% vs the prior close of $22.02. Day range $21.67–$22.25, opened at $22.23.
- Volume was 975.40K shares, 1.2x its 50-day average of 827.19K.
- Price is -17.4% vs its 50-day average ($26.49) and -38.6% vs its 200-day average ($35.61).
- 52-week range $21.43–$50.79; today's close sits at 1% of that range, 56.9% below the 52-week high.
Oct 2, 2026 — COLL rises 0.8% to $22.02
- Closed at $22.02, +0.82% vs the prior close of $21.84. Day range $21.64–$22.38, opened at $21.97.
- Volume was 694.00K shares, 0.8x its 50-day average of 818.37K.
- Price is -17.7% vs its 50-day average ($26.76) and -38.4% vs its 200-day average ($35.75).
- 52-week range $21.43–$50.79; today's close sits at 2% of that range, 56.6% below the 52-week high.
COLL latest news & SEC filings
Every SEC filing by or about COLL in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 30, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 24, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $199.88M (prior year $188.00M) (+6.3% vs Jun 30, 2025)
- Net income: -$15.05M (prior year $11.98M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.46 (prior year $0.34) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 5, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 31, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 17, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jul 15, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jun 30, 2026 · Form 8-K/A — Current report (amended)
Amended current report
- Exhibits / financial statements only (Item 9.01).
Things to know before you trade COLL
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.10% (largest 4.6%).
- Liquidity: about 760.21K shares (≈$17.63M) trade per day on average.
- 52-week position: $23.19 vs a range of $21.43–$50.79 (6% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: John Gordon Freund sold 20 shares on May 18, 2026.
- Latest filings: 8-K Aug 13, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Share count: 32.56M shares outstanding (Jul 31, 2026), +3.3% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
COLL market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 23.40 | 23.41 | 22.85 | 23.19 | 558.64K |
| Oct 15, 2026 | 23.06 | 24.04 | 23.06 | 23.18 | 1.00M |
| Oct 14, 2026 | 21.65 | 22.56 | 21.47 | 22.51 | 920.20K |
| Oct 13, 2026 | 22.05 | 22.21 | 21.46 | 21.53 | 846.40K |
| Oct 12, 2026 | 22.14 | 22.28 | 21.78 | 22.05 | 528.70K |
| Oct 9, 2026 | 22.01 | 22.40 | 21.77 | 22.09 | 438.30K |
| Oct 8, 2026 | 22.03 | 22.18 | 21.78 | 22.11 | 532.90K |
| Oct 7, 2026 | 21.88 | 22.15 | 21.73 | 21.93 | 783.50K |
| Oct 6, 2026 | 22.06 | 22.32 | 21.67 | 21.88 | 634.00K |
| Oct 5, 2026 | 22.23 | 22.25 | 21.67 | 21.87 | 975.40K |
| Oct 2, 2026 | 21.97 | 22.38 | 21.64 | 22.02 | 694.00K |
| Oct 1, 2026 | 21.94 | 22.28 | 21.43 | 21.84 | 1.00M |
| Sep 30, 2026 | 22.14 | 22.33 | 21.82 | 21.82 | 811.60K |
| Sep 29, 2026 | 22.61 | 22.92 | 21.62 | 22.23 | 1.02M |
| Sep 28, 2026 | 22.62 | 23.17 | 22.35 | 22.63 | 687.40K |
| Sep 25, 2026 | 22.58 | 22.91 | 22.29 | 22.53 | 503.40K |
| Sep 24, 2026 | 22.27 | 22.77 | 21.90 | 22.64 | 650.10K |
| Sep 23, 2026 | 23.23 | 23.69 | 21.77 | 22.45 | 878.40K |
| Sep 22, 2026 | 23.46 | 23.51 | 22.64 | 22.78 | 808.20K |
| Sep 21, 2026 | 22.78 | 23.23 | 22.50 | 23.04 | 928.30K |
About Collegium Pharmaceutical
Collegium Pharmaceutical (COLL) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in STOUGHTON, MA. State of incorporation: VA. Fiscal year ends December 31. SEC CIK 1267565.
COLL board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Garen G Bohlin | Director | May 18, 2026 |
| Rita J. Balice-Gordon | Director | May 18, 2026 |
| John A. Fallon | Director | Nov 14, 2025 |
| John Gordon Freund | Director | May 20, 2026 |
| Donovan Michael Glancy | Director | May 18, 2026 |
| Vikram Karnani | President and CEO | Feb 12, 2026 |
| Nancy Lurker | Director | May 18, 2026 |
| Carlos V Paya | Director | May 18, 2026 |
| Gino Santini | Director | Jun 10, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| David Dieter | EVP & General Counsel | Apr 3, 2026 |
| Scott Dreyer | EVP & Chief Commercial Officer | Mar 5, 2026 |
| Vikram Karnani | President and CEO | Feb 12, 2026 |
| Thomas B Smith | EVP and Chief Medical Officer | Feb 12, 2026 |
| Colleen Tupper | EVP & Chief Financial Officer | Feb 12, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 18, 2026 | John Gordon Freund | Sale | 20 | $34.05 |
| May 18, 2026 | John Gordon Freund | Sale | 20 | $34.05 |
| May 18, 2026 | John Gordon Freund | Sale | 20 | $34.05 |
| May 18, 2026 | John Gordon Freund | Sale | 20 | $34.05 |
| May 15, 2026 | John Gordon Freund | Sale | 4,127 | $34.54 |
| May 15, 2026 | John Gordon Freund | Sale | 4,127 | $34.54 |
| May 15, 2026 | John Gordon Freund | Sale | 4,127 | $34.54 |
| May 15, 2026 | John Gordon Freund | Sale | 4,127 | $34.54 |
| May 13, 2026 | Nancy Lurker | Sale | 4,500 | $35.97 |
| May 13, 2026 | Nancy Lurker | Sale | 4,500 | $35.97 |
| May 13, 2026 | Nancy Lurker | Sale | 4,500 | $35.97 |
| May 13, 2026 | Nancy Lurker | Sale | 4,500 | $35.97 |
| May 11, 2026 | Garen G Bohlin | Sale | 8,700 | $37.18 |
| May 11, 2026 | Garen G Bohlin | Sale | 8,700 | $37.18 |
| May 11, 2026 | Garen G Bohlin | Sale | 8,700 | $37.18 |
COLL financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $780.57M | $62.87M | 1.73 | $329.32M |
| Dec 31, 2024 | $631.45M | $69.19M | 1.86 | $204.98M |
| Dec 31, 2023 | $566.77M | $48.16M | 1.29 | $274.75M |
| Dec 31, 2022 | $463.93M | $-25.00M | -0.74 | $124.23M |
| Dec 31, 2021 | $276.87M | $71.52M | 1.86 | $103.56M |
Latest balance sheet: total assets $2.14B, total liabilities $1.82B, cash $129.47M (as of Jun 30, 2026).
COLL earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $29.11 |
| May 7, 2026 | 8-K Item 2.02 (results) | $39.33 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $44.22 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $40.66 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $32.94 |
| May 8, 2025 | 8-K Item 2.02 (results) | $27.27 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $28.42 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $34.71 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| Jul 29, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Feb 22, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on COLL
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.